Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: An international multicenter 2 × 2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment

Files

Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial___Resumen.pdf (207.02 KB)

Date

2015

Type:

Artículo

Collections

Artículos Medicina y Ciencias de la Salud

Descargas totales

47

Vistas totales

1
Gestores bibliográficos

Authors

item.contributor.advisor

ORCID:

Journal Title

Journal ISSN

Volume Title

Publisher

Sage Publications

item.page.isbn

item.page.issn

item.page.issne

item.page.doiurl

URI

http://hdl.handle.net/11447/1195
 http://dx.doi.org/10.1111/ijs.12486

item.page.extent

11

item.page.accessRights

item.page.other

item.page.references

Abstract

RATIONALE: Controversy exists over the optimal dose of intravenous (i.v.) recombinant tissue plasminogen activator (rt-PA) and degree of blood pressure (BP) control in acute ischaemic stroke (AIS). As...

Description

item.page.coverage.spatial

item.page.sponsorship

Citation

Int J Stroke. 2015 Jul;10(5):778-788

Keywords

Alteplase , Acute ischaemic stroke , Dose , Hypertension , Rt-PA , Thrombolysis

item.page.dc.rights

item.page.dc.rights.url

Estadísticas de uso
1 0,8 0,5 0,3 0
Septiembre 2025Octubre 2025Noviembre 2025Diciembre 2025Enero 2026Febrero 2026Marzo 2026

Implementado por OpenGeek Services